AHA Coding Clinic® for HCPCS - 2017 Quarter 4; For Your Information
Pass-through status granted to eight drugs and biologicals effective January 1, 2018
HCPCS Code Long Description C9014 Injection, cerliponase alfa, 1 mg C9015 Injection, c-1 esterase inhibitor (human), haegarda, 10 units C9016 Injection, triptorelin extended release, 3.75 mg C9024 Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine C9028 Injection, inotuzumab ozogamicin, 0.1 mg C9029 Injection, guselkumab, 1 mg J7345 Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J9203 Injection, gemtuzumab ozogamicin, 0.1 mg ...
Subscribe or sign in to view the full article.
Article Overview
This brief coding update covers Medicare HCPCS pass-through status for a set of drugs and biologicals effective January 1, 2018. It is relevant for hospital outpatient coders, billing staff, and reimbursement professionals who track newly reportable HCPCS codes and payment-related updates. The article focuses on the identifiers assigned to these products and provides the source context for a limited effective-date update.
Why This Topic Matters
Pass-through updates can affect charge capture, claims reporting, and payment workflow for facilities and coding teams that bill outpatient drug and biological services. Reviewing the article helps users identify which HCPCS identifiers were newly recognized in this update and understand the scope of the change.
What You Will Learn
- Which HCPCS drug and biological identifiers were included in the January 1, 2018 pass-through update.
- The general scope of the article as a payment and reporting update.
- Why pass-through status updates are monitored by coding and billing teams.
- intended_audiences=[
Who Should Read This
- Hospital outpatient coders
- Billing staff
- Reimbursement specialists
- Revenue cycle teams
- Health information management professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com